D
Douglas W. P. Hay
Researcher at GlaxoSmithKline
Publications - 55
Citations - 4535
Douglas W. P. Hay is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Receptor & Agonist. The author has an hindex of 30, co-authored 53 publications receiving 4435 citations. Previous affiliations of Douglas W. P. Hay include University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14
Robert S. Ames,Henry M. Sarau,Johathan K. Chambers,Robert N. Willette,Nambi Aiyar,Anne M. Romanic,Calvert Louden,James J. Foley,Charles F. Sauermelch,Robert W. Coatney,Zhaohui Ao,Jyoti Disa,Stephen Dudley Holmes,Jeffrey M. Stadel,John D. Martin,Wu-Schyong Liu,George I. Glover,Shelagh Wilson,Dean E. McNulty,Catherine E. Ellis,Nabil Elshourbagy,Usman Shabon,John J. Trill,Douglas W. P. Hay,Eliot H. Ohlstein,Derk J. Bergsma,Stephen A. Douglas +26 more
TL;DR: The identification of an orphan human G-protein-coupled receptor homologous to rat GPR14 and expressed predominantly in cardiovascular tissue, which functions as a U-II receptor, the most potent mammalian vasoconstrictor identified so far.
Journal ArticleDOI
The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo
Nan Chiang,Charles N. Serhan,Sven-Erik Dahlén,Jeffrey M. Drazen,Douglas W. P. Hay,G. Enrico Rovati,Takao Shimizu,Takehiko Yokomizo,Charles Brink +8 more
TL;DR: The purpose of this review is to highlight the molecular characterization of the ALX receptor and provide an overview of theALX-LXA4 axis responsible for anti-inflammatory and proresolving signals in vivo.
Journal ArticleDOI
Identification, Molecular Cloning, Expression, and Characterization of a Cysteinyl Leukotriene Receptor
Henry M. Sarau,Robert S. Ames,Jon K. Chambers,Catherine E. Ellis,Nabil Elshourbagy,James J. Foley,Dulcie B. Schmidt,Roseanna M. Muccitelli,Owen Jenkins,Paul R. Murdock,Nicole C. Herrity,Wendy S. Halsey,Ganesh M. Sathe,Alison I. Muir,Parvathi Nuthulaganti,George M. Dytko,Peter T. Buckley,Shelagh Wilson,Derk J. Bergsma,Douglas W. P. Hay +19 more
TL;DR: The discovery of this CysLTR receptor, which has characteristics of the purported CysLT(1) receptor subtype, should assist in the elucidation of the pathophysiological roles of the Cys LTs and in the identification of additional receptor subtypes.
Journal ArticleDOI
Effects of LTD4 on Human Airway Smooth Muscle Cell Proliferation, Matrix Expression, and Contraction In Vitro: Differential Sensitivity to Cysteinyl Leukotriene Receptor Antagonists
Reynold A. Panettieri,Elaine M. L. Tan,Vincenzo Ciocca,Mark A. Luttmann,Thomas B. Leonard,Douglas W. P. Hay +5 more
TL;DR: Data indicate that LTD4 augments growth factor-induced HASM proliferation but does not alter the expression of various extracellular matrix components, which provides preliminary evidence that CysLTs may play a role in airways remodeling in asthma.
Journal ArticleDOI
International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors
Charles Brink,Sven-Erik Dahlén,Jeffrey M. Drazen,Jilly F. Evans,Douglas W. P. Hay,Simonetta Nicosia,Charles N. Serhan,Takao Shimizu,Takehiko Yokomizo +8 more
TL;DR: The aim of this review is to provide the molecular evidence as well as the properties and significance of the leukotriene and lipoxin receptors, which has lead to the present nomenclature.